Koyama Kazuya, Iwamoto Hidetaka, Takahashi Kenji, Okada Tetsuhiro, Kawabata Hidemasa, Kitano Yohei, Tanabe Hiroki, Fujiya Mikihiro, Okumura Toshikatsu, Mizukami Yusuke
Division of Gastroenterology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka Higashi, Asahikawa, Hokkaido, 078-8510, Japan.
Genetic Oncology Department, Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan.
Clin J Gastroenterol. 2025 Feb;18(1):183-187. doi: 10.1007/s12328-024-02076-w. Epub 2024 Dec 7.
We report the rare case of severe cognitive disorder and ataxia caused by entrectinib in a patient with NTRK1 fusion gene-positive intrahepatic cholangiocarcinoma. The case was a 56-year-old woman after nine courses of GCS therapy. The patient experienced grade 1 muscle weakness on day 4 and grade 3, cognitive disorder on day 7 after receiving entrectinib, which led to hospitalization. The symptoms were reversible and tended to improve after withdrawal of entrectinib. It is crucial to increase awareness of TRKi-specific adverse events and their proper management.
我们报告了1例由恩曲替尼引起的严重认知障碍和共济失调的罕见病例，该患者为NTRK1融合基因阳性的肝内胆管癌患者。该病例为一名56岁女性，接受了9个疗程的GCS治疗。患者在接受恩曲替尼治疗后第4天出现1级肌肉无力，第7天出现3级认知障碍，随后住院治疗。这些症状是可逆的，在停用恩曲替尼后病情趋于改善。提高对TRKi特异性不良事件及其合理管理的认识至关重要。
